Article
High sensitive mutation analysis on KRAS gene using LNA/DNA chimeras as PCR amplification blockers of wild-type alleles.
Molecular and cellular probes - 1 Dec 2010
Huang Qing, Wang Gui-Yu, Huang Jun-Fu, Zhang Bo, Fu Wei-Ling
Abstract excerpt
The missense mutations at codons 12 and 13 of KRAS gene have been confirmed as a predictor of nonresponse to EGFR-targeted therapy with monoclonal antibodies cetuximab and panitumumab in patients with metastatic colorectal carcinoma (mCRC). Because of the intra-tumor heterogeneity at genetic levels, it is important to develop sensitive and selective assays to detect above KRAS mutation of rare mutated cells in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.